A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization
- Status
- COMPLETED
- Phase
- N/A
Clinical Trials Related to Unresectable Hepatocellular Carcinoma
Related studies linked through entity extraction aliases.
Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE3
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
- Status
- RECRUITING
- Phase
- PHASE2
Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China
- Status
- COMPLETED
- Phase
- N/A
Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1
Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension
- Status
- RECRUITING
- Phase
- N/A
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE1
Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
- Status
- RECRUITING
- Phase
- PHASE2
Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
- Status
- COMPLETED
- Phase
- N/A
A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC
- Status
- UNKNOWN
- Phase
- PHASE2
Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Himalaya Early Access Program
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
DEB-TACE+HAIC vs. HAIC for Large HCC
- Status
- RECRUITING
- Phase
- PHASE3
A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)
- Status
- UNKNOWN
- Phase
- PHASE2